Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 in Recurrent Respiratory Papillomatosis
NCT03707587Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2018
- Primary completion
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in recurrent respiratory papillomatosis (RRP), sponsored by National Cancer Institute. Started Dec 2018; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT03707587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707587.